Yee Chi-Hang, Chung Yuen-Hei, Ko Ivan Ching-Ho, Wong Chris Ho-Ming, Mok Alex, Teoh Jeremy Yuen-Chun, Chiu Peter Ka-Fung, Ng Chi-Fai
S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
BMC Urol. 2025 Feb 25;25(1):39. doi: 10.1186/s12894-025-01717-7.
Long-acting triptorelin (LAT) (22.5 mg) is a gonadotropin-releasing hormone (GnRH) agonist used in men with prostate cancer. This study investigated the prescription pattern of LAT in a real-world setting and its efficacy.
PATIENTS & METHODS: This was a retrospective review of patients in a tertiary center who were prescribed LAT for prostate cancer from January 2018 to March 2023 after the introduction of LAT in the territory. Demographic data were collected, and LAT prescription patterns were reviewed. These patterns included the indication and duration of prescription, testosterone suppression and characteristics of the primary prostate cancer.
A total of 237 prostate cancer patients were prescribed LAT in the study period. The indications for LAT included metastatic prostate cancer (50.6%), neoadjuvant/adjuvant therapy for radiotherapy (28.7%) and neoadjuvant therapy for radical prostatectomy (5.1%). Among the cohort, 41.4% of the patients were receiving short-acting triptorelin (11.25 mg) before LAT initiation, 15.2% were receiving other GnRH agonists, and 15.6% were receiving GnRH antagonists. The median age at the first dose of LAT and the median treatment duration were 72 (53-94) years and 30 (6-72) months, respectively. During the study period, 92.0% of the patients did not receive another form of hormonal treatment other than LAT. A total of 121 (51.1%) patients had their testosterone level checked after LAT initiation. The median time interval of testosterone measurement after LAT initiation was 8 (1-47) months, with 98.3% of the patients having a testosterone level < 1.7 nmol/L and 92.6% having a level < 0.7 nmol/L. Among the cohort, 1 patient stopped LAT due to hot flashes and muscle weakness.
The LAT adherence rate was high in the setting of hormonal treatment for prostate cancer. Testosterone suppression was satisfactory after the initiation of LAT and was generally well tolerated.
长效曲普瑞林（LAT，22.5毫克）是一种用于前列腺癌男性患者的促性腺激素释放激素（GnRH）激动剂。本研究调查了LAT在实际临床环境中的处方模式及其疗效。
这是一项对某三级中心患者的回顾性研究，这些患者在该地区引入LAT后，于2018年1月至2023年3月期间因前列腺癌被处方使用LAT。收集了人口统计学数据，并对LAT的处方模式进行了回顾。这些模式包括处方的适应证和持续时间、睾酮抑制情况以及原发性前列腺癌的特征。
在研究期间，共有237例前列腺癌患者被处方使用LAT。LAT的适应证包括转移性前列腺癌（50.6%）、放疗的新辅助/辅助治疗（28.7%）以及根治性前列腺切除术的新辅助治疗（5.1%）。在该队列中，41.4%的患者在开始使用LAT之前接受短效曲普瑞林（11.25毫克）治疗，15.2%的患者接受其他GnRH激动剂治疗，15.6%的患者接受GnRH拮抗剂治疗。首次使用LAT时的中位年龄和中位治疗持续时间分别为72（53 - 94）岁和30（6 - 72）个月。在研究期间，92.0%的患者除LAT外未接受其他形式的激素治疗。共有121例（51.1%）患者在开始使用LAT后检查了睾酮水平。开始使用LAT后睾酮测量的中位时间间隔为8（1 - 47）个月，98.3%的患者睾酮水平<1.7纳摩尔/升，92.6%的患者睾酮水平<0.7纳摩尔/升。在该队列中，1例患者因潮热和肌肉无力停止使用LAT。
在前列腺癌激素治疗中，LAT的依从率较高。开始使用LAT后睾酮抑制效果良好，且总体耐受性较好。
